Publications by authors named "Ansgar Weyergraf"
Article Synopsis
- - Palmoplantar pustulosis (PPP) is a painful chronic skin disorder affecting the palms and soles, with no approved treatments in Europe and the USA, although guselkumab is approved in Japan.
- - A phase II study involving 50 Caucasian patients showed that administering 100 mg of guselkumab subcutaneously for 24 weeks significantly reduced the severity of PPP, with a median improvement of 59.6% in the PPP severity index.
- - The study concluded that guselkumab could be a viable treatment option for Caucasian patients suffering from moderate-to-severe PPP, as indicated by substantial improvements in both clinical and quality of life measures.
Background: Palmoplantar pustulosis (PPP) is a recalcitrant chronic inflammatory skin disease. Data relevant for the medical care of patients with PPP are scarce. Thus, the aim of this work was to investigate the disease burden, clinical characteristics, and comorbidity of PPP patients in Germany.
View Article and Find Full Text PDFBackground: In the literature as well as in existing psoriasis guidelines, only little evidence is available on combination regimens with systemic antipsoriatic agents. However, if systemic monotherapy is not efficacious enough to control the disease, a combination therapy might be necessary.
Objective: To evaluate the use of fumaric acid esters (FAEs) in combination with other antipsoriatic agents in 6 specialized dermatological departments in Germany.
This first German evidence-based guideline for cutaneous melanoma was developed under the auspices of the German Dermatological Society (DDG) and the Dermatologic Cooperative Oncology Group (DeCOG) and funded by the German Guideline Program in Oncology. The recommendations are based on a systematic literature search, and on the consensus of 32 medical societies, working groups and patient representatives. This guideline contains recommendations concerning diagnosis, therapy and follow-up of melanoma.
View Article and Find Full Text PDFBackground: Monotherapy with TNF-α inhibitors does not always produce a sufficient response in psoriasis patients. Combinations of TNF-α antagonists such as adalimumab with systemic antipsoriatic therapies such as methotrexate are not approved for use in psoriasis, and the published data are scarce.
Patients And Methods: The charts of 39 psoriasis patients from 6 dermatology departments were reviewed retrospectively.